de Morgan Stanley State Street SPDR S&P Pharmaceuticals ETF XPH Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 20.8 M | Comprar |
314,226
+26,638
| +9% | +USD 1.56 M | ﹤0.01% | 3060 |
|
|
2026
Q1 | USD 15.6 M | Comprar |
287,588
+146,357
| +104% | +USD 8.16 M | ﹤0.01% | 3183 |
|
|
2025
Q4 | USD 7.91 M | Vender |
141,231
-406,036
| -74% | -USD 21 M | ﹤0.01% | 3812 |
|
|
2025
Q3 | USD 26.2 M | Comprar |
547,267
+51,132
| +10% | +USD 2.29 M | ﹤0.01% | 2619 |
|
|
2025
Q2 | USD 20.1 M | Vender |
496,135
-2,814
| -0.6% | -USD 113 k | ﹤0.01% | 2800 |
|
|
2025
Q1 | USD 21.9 M | Vender |
498,949
-114,489
| -19% | -USD 5.05 M | ﹤0.01% | 2598 |
|
|
2024
Q4 | USD 26.4 M | Comprar |
613,438
+503,697
| +459% | +USD 22.9 M | ﹤0.01% | 2488 |
|
|
2024
Q3 | USD 4.87 M | Vender |
109,741
-17,927
| -14% | -USD 768 k | ﹤0.01% | 3978 |
|
|
2024
Q2 | USD 5.08 M | Vender |
127,668
-55,367
| -30% | -USD 2.24 M | ﹤0.01% | 3860 |
|
|
2024
Q1 | USD 7.89 M | Vender |
183,035
-207,943
| -53% | -USD 8.96 M | ﹤0.01% | 3530 |
|
|
2023
Q4 | USD 16.3 M | Comprar |
390,978
+72,348
| +23% | +USD 2.74 M | ﹤0.01% | 2890 |
|
|
2023
Q3 | USD 12.7 M | Vender |
318,630
-65,513
| -17% | -USD 2.77 M | ﹤0.01% | 2901 |
|
|
2023
Q2 | USD 15.7 M | Vender |
384,143
-198,929
| -34% | -USD 8.21 M | ﹤0.01% | 2719 |
|
|
2023
Q1 | USD 23.9 M | Vender |
583,072
-57,363
| -9% | -USD 2.41 M | ﹤0.01% | 2223 |
|
|
2022
Q4 | USD 26.2 M | Vender |
640,435
-138,584
| -18% | -USD 5.77 M | ﹤0.01% | 2065 |
|
|
2022
Q3 | USD 31.3 M | Comprar |
779,019
+109,463
| +16% | +USD 4.68 M | ﹤0.01% | 1726 |
|
|
2022
Q2 | USD 28.1 M | Comprar |
669,556
+154,928
| +30% | +USD 6.5 M | ﹤0.01% | 1919 |
|
|
2022
Q1 | USD 23.3 M | Vender |
514,628
-22,685
| -4% | -USD 997 k | ﹤0.01% | 1951 |
|
|
2021
Q4 | USD 24.8 M | Comprar |
537,313
+134,317
| +33% | +USD 6.36 M | ﹤0.01% | 1936 |
|
|
2021
Q3 | USD 19.1 M | Vender |
402,996
-10,659
| -3% | -USD 530 k | ﹤0.01% | 2135 |
|
|
2021
Q2 | USD 21.4 M | Vender |
413,655
-66,704
| -14% | -USD 3.35 M | ﹤0.01% | 2069 |
|
|
2021
Q1 | USD 24.2 M | Vender |
480,359
-17,078
| -3% | -USD 910 k | ﹤0.01% | 1740 |
|
|
2020
Q4 | USD 25.9 M | Comprar |
497,437
+83,054
| +20% | +USD 3.97 M | ﹤0.01% | 1570 |
|
|
2020
Q3 | USD 18 M | Vender |
414,383
-25,374
| -6% | -USD 1.11 M | ﹤0.01% | 1560 |
|
|
2020
Q2 | USD 18.9 M | Vender |
439,757
-373,502
| -46% | -USD 15.4 M | ﹤0.01% | 1440 |
|
|
2020
Q1 | USD 29.3 M | Comprar |
813,259
+469,144
| +136% | +USD 20 M | 0.01% | 1033 |
|
|
2019
Q4 | USD 15.7 M | Vender |
344,115
-3,198
| -0.9% | -USD 127 k | ﹤0.01% | 1888 |
|
|
2019
Q3 | USD 12.4 M | Vender |
347,313
-63,409
| -15% | -USD 2.36 M | ﹤0.01% | 1913 |
|
|
2019
Q2 | USD 16.4 M | Vender |
410,722
-312,081
| -43% | -USD 12.3 M | ﹤0.01% | 1653 |
|
|
2019
Q1 | USD 30.1 M | Vender |
722,803
-126,317
| -15% | -USD 5.13 M | 0.01% | 1142 |
|
|
2018
Q4 | USD 31.1 M | Vender |
849,120
-29,199
| -3% | -USD 1.25 M | 0.01% | 1102 |
|
|
2018
Q3 | USD 42.6 M | Comprar |
878,319
+295,396
| +51% | +USD 14 M | 0.01% | 1060 |
|
|
2018
Q2 | USD 25.1 M | Vender |
582,923
-234,618
| -29% | -USD 9.9 M | 0.01% | 1437 |
|
|
2018
Q1 | USD 34.2 M | Comprar |
817,541
+250,687
| +44% | +USD 10.9 M | 0.01% | 1197 |
|
|
2017
Q4 | USD 24.7 M | Vender |
566,854
-74,668
| -12% | -USD 3.18 M | 0.01% | 1487 |
|
|
2017
Q3 | USD 27.3 M | Comprar |
641,522
+23,517
| +4% | +USD 997 k | 0.01% | 1328 |
|
|
2017
Q2 | USD 26.6 M | Comprar |
618,005
+1,327
| +0.2% | +USD 55.9 k | 0.01% | 1298 |
|
|
2017
Q1 | USD 25.8 M | Comprar |
616,678
+294,560
| +91% | +USD 12 M | 0.01% | 1355 |
|
|
2016
Q4 | USD 12.6 M | Comprar |
322,118
+43,527
| +16% | +USD 1.77 M | ﹤0.01% | 2010 |
|
|
2016
Q3 | USD 12.3 M | Vender |
278,591
-94,674
| -25% | -USD 4.3 M | ﹤0.01% | 1841 |
|
|
2016
Q2 | USD 15.6 M | Vender |
373,265
-114,495
| -23% | -USD 4.85 M | 0.01% | 1622 |
|
|
2016
Q1 | USD 19.6 M | Vender |
487,760
-352,346
| -42% | -USD 14.9 M | 0.01% | 1319 |
|
|
2015
Q4 | USD 43 M | Vender |
840,106
-22,819
| -3% | -USD 1.16 M | 0.02% | 876 |
|
|
2015
Q3 | USD 40.5 M | Vender |
862,925
-317,911
| -27% | -USD 19.2 M | 0.02% | 913 |
|
|
2015
Q2 | USD 73.6 M | Comprar |
1,180,836
+57,310
| +5% | +USD 3.57 M | 0.03% | 655 |
|
|
2015
Q1 | USD 69.4 M | Vender |
1,123,526
-15,550
| -1% | -USD 922 k | 0.03% | 667 |
|
|
2014
Q4 | USD 61.5 M | Vender |
1,139,076
-22,782
| -2% | -USD 1.24 M | 0.02% | 738 |
|
|
2014
Q3 | USD 61.6 M | Comprar |
1,161,858
+4,620
| +0.4% | +USD 235 k | 0.02% | 727 |
|
|
2014
Q2 | USD 60.1 M | Vender |
1,157,238
-91,456
| -7% | -USD 4.41 M | 0.02% | 709 |
|
|
2014
Q1 | USD 58.4 M | Comprar |
1,248,694
+183,526
| +17% | +USD 8.67 M | 0.02% | 677 |
|
|
2013
Q4 | USD 46.9 M | Vender |
1,065,168
-4,482
| -0.4% | -USD 187 k | 0.02% | 775 |
|
|
2013
Q3 | USD 41.2 M | Comprar |
1,069,650
+20,480
| +2% | +USD 774 k | 0.02% | 769 |
|
|
2013
Q2 | USD 37 M | Comprar |
+1,049,170
| Nuevas | +USD 35.4 M | 0.02% | 792 |
|
Otros fondos que tienen XPH en su cartera
Posición de Morgan Stanley en XPH: resumen de T2 2026
Morgan Stanley aumentó su participación en State Street SPDR S&P Pharmaceuticals ETF (XPH) en 9.3% durante T2 2026, al comprar aproximadamente USD 1.56 M y elevar la posición a 314,226 acciones con un valor de USD 20.8 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #3060.
Morgan Stanley reportó por primera vez una posición en XPH en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 73.6 M en T2 2015. Al cierre de T2 2026, 92 fondos que sigue Wall St. Rank mantienen una posición en XPH.
- Al cierre de T2 2026, Morgan Stanley tenía 314,226 acciones de State Street SPDR S&P Pharmaceuticals ETF con un valor de USD 20.8 M.
- Morgan Stanley compró 26,638 acciones de State Street SPDR S&P Pharmaceuticals ETF en T2 2026, por un monto estimado de USD 1.56 M.
- State Street SPDR S&P Pharmaceuticals ETF representó ﹤0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 3060.
- Morgan Stanley reportó por primera vez una posición en State Street SPDR S&P Pharmaceuticals ETF en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de Morgan Stanley en State Street SPDR S&P Pharmaceuticals ETF alcanzó su máximo de USD 73.6 M en T2 2015.
- Al cierre de T2 2026, 92 fondos que sigue Wall St. Rank tenían State Street SPDR S&P Pharmaceuticals ETF en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.